Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.
Adding vistusertib to weekly paclitaxel does not appear to help improve clinical outcomes in patients with platinum-resistant or refractory ovarian high-grade serous carcinoma (PR-HGSC), according to the results of a phase II study.
In the final overall survival (OS) analysis of the phase III PAOLA-1*/ENGOT-ov25 trial, the addition of olaparib to bevacizumab provided a survival benefit for women with newly diagnosed advanced ovarian cancer with HRD**-positive (HRD+) tumours.
Pretreatment sarcopenia appears to worsen survival in patients with gynaecologic cancers, such as ovarian (OC), endometrial (EC), and cervical (CC), reports a study. Including this assessment into cancer management may help improve prognosis.
New drug applications approved by US FDA as of 01 - 15 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Trabectedin falls short of meeting the prespecified antitumour activity criteria in patients with advanced ovarian (OC) or uterine carcinosarcoma (UC), according to the results of a phase II trial. However, there appears to be a modest clinical benefit in a group of heavily pretreated patients.
CHK1 inhibition with prexasertib appears to have durable activity in some patients with recurrent ovarian cancer regardless of clinical characteristics, BRCA status, or prior therapies, according to the results of a phase II trial.
A combination regimen comprising apatinib, a small-molecule TKI*, and pegylated liposomal doxorubicin (PLD) led to improved progression-free survival (PFS) in women with platinum-resistant recurrent ovarian cancer (PROC), results of the APPROVE trial suggest.
First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.
Trabectedin did not improve overall survival (OS) or progression-free survival (PFS) compared with chemotherapy in women with recurrent ovarian, primary peritoneal, or fallopian tube cancer and BRCA mutation or BRCAness phenotypes, according to results of the phase III MITO23 trial.
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.